Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD
Novel subcutaneous delivery may offer a more patient-friendly…Read More
You might also be interested in reading ClawdBot (now Moltbot) Generates 247% Profit in 24 Hours on Polymarket.